COMPANY
Agios Pharmaceuticals
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Hemolytic Anemia Sales Specialist / Senior Hemolytic Anemia Sales Specialist (National) | Agios Pharmaceuticals HQ | Not stated | Oct 15, 2026 |
| AD, Field Access Management (West) | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 |
| Director, Human Resources Business Partner | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 |
| Associate Director, Medical Review Lead, MSRM | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 |
| Associate Director, Value, Access, & Pricing (Ex-US) | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 |
Timeline
- Trial start Phase 2/Phase 3: A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera source ↗
- Trial start Phase 3: A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia source ↗
- Trial start Phase 3: A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) source ↗
- Trial start Phase 3: A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) source ↗
- Trial start Phase 1: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria source ↗
- Trial start Phase 2: A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy source ↗
- FDA FDA New indication / efficacy supplement: AQVESME; PYRUKYND (mitapivat sulfate) — NDA216196/3, Dec 23, 2025. Applicant at approval: Agios Pharmaceuticals, Inc. source ↗
- Trial start Phase 1: A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants source ↗
- Trial start Phase 2: A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) source ↗
- Trial start Phase 1: A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants source ↗
- Trial start Phase 1: Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants source ↗
- Trial start Phase 1: Single and Multiple Ascending Dose Study and Food Effect Study for AG181 source ↗
- Trial start Phase 4: A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study source ↗
- Trial start Phase 1: A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function source ↗
- Trial start Phase 2: A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Perio source ↗
- Trial start Phase 2/Phase 3: A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) source ↗
- Trial start Phase 3: A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) source ↗
- Trial start Phase 3: A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) source ↗
- Trial start —: Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008 source ↗
- Trial start —: Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO) source ↗
- Trial start Phase 1: A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants source ↗
- Trial start Phase 1: A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants source ↗
- Trial start Phase 1: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease source ↗
Upcoming milestones
- May 31, 2027 (ESTIMATED) · · Pyruvate Kinase Deficiency Global Longitudinal Registry · NCT03481738
- Jan 17, 2028 (ESTIMATED) · Phase 1 · A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria · NCT07241234
- 2029-03 (ESTIMATED) · Phase 3 · A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia · NCT07517133
- 2029-06 (ESTIMATED) · Phase 3 · A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) · NCT07506863
- 2029-08 (ESTIMATED) · Phase 4 · A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study · NCT05777993
- 2029-08 (ESTIMATED) · Phase 3 · A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) · NCT07656415
- 2030-08 (ESTIMATED) · Phase 2/Phase 3 · A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera · NCT07859423
Clinical trials (lead sponsor) Showing 50 of 52
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07859423 | A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera | Phase 2/Phase 3 | Not yet recruiting | 2026-11 | 2030-08 (estimated) |
| NCT05777993 | A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study | Phase 4 | Enrolling by invitation | Jul 6, 2023 | 2029-08 (estimated) |
| NCT07656415 | A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) | Phase 3 | Recruiting | Jul 21, 2026 | 2029-08 (estimated) |
| NCT03481738 | Pyruvate Kinase Deficiency Global Longitudinal Registry | Not listed | Active, not recruiting | Apr 23, 2018 | May 31, 2027 (estimated) |
| NCT07517133 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia | Phase 3 | Recruiting | 2026-09 | 2029-03 (estimated) |
| NCT05144256 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period | Phase 3 | Active, not recruiting | Jun 8, 2022 | May 3, 2024 (actual) |
| NCT07506863 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | Phase 3 | Recruiting | 2026-09 | 2029-06 (estimated) |
| NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Phase 2 | Active, not recruiting | Nov 7, 2022 | Mar 17, 2026 (actual) |
| NCT04770753 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) | Phase 3 | Active, not recruiting | Dec 20, 2021 | Nov 13, 2023 (actual) |
| NCT06924970 | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) | Phase 2 | Active, not recruiting | May 1, 2025 | May 12, 2026 (actual) |
| NCT04770779 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | Phase 3 | Active, not recruiting | Nov 30, 2021 | Apr 11, 2024 (actual) |
| NCT07241234 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria | Phase 1 | Recruiting | Apr 17, 2026 | Jan 17, 2028 (estimated) |
| NCT05175105 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period | Phase 3 | Active, not recruiting | Jun 6, 2022 | Dec 13, 2024 (actual) |
| NCT07075640 | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants | Phase 1 | Active, not recruiting | Jul 7, 2025 | Feb 11, 2026 (actual) |
| NCT05031780 | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | Phase 2/Phase 3 | Active, not recruiting | Feb 11, 2022 | Oct 30, 2025 (actual) |
| NCT02476916 | A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency | Phase 2 | Completed | Jun 26, 2015 | May 8, 2017 (actual) |
| NCT06286046 | A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy | Phase 2 | Withdrawn | 2026-03 | 2027-05 (estimated) |
| NCT03692052 | A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia | Phase 2 | Active, not recruiting | Mar 20, 2019 | Aug 20, 2020 (actual) |
| NCT06286033 | Single and Multiple Ascending Dose Study and Food Effect Study for AG181 | Phase 1 | Completed | Feb 20, 2024 | Oct 9, 2025 (actual) |
| NCT03853798 | Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007 | Phase 3 | Completed | Mar 21, 2019 | Jul 3, 2024 (actual) |
| NCT06745271 | A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants | Phase 1 | Completed | Dec 20, 2024 | Feb 21, 2025 (actual) |
| NCT06648824 | Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants | Phase 1 | Completed | Oct 17, 2024 | Dec 3, 2024 (actual) |
| NCT04536792 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease | Phase 1 | Completed | Jul 10, 2020 | Dec 19, 2023 (actual) |
| NCT04995315 | Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008 | Not listed | Completed | Jul 2, 2021 | Sep 22, 2023 (actual) |
| NCT05610657 | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function | Phase 1 | Completed | Jan 10, 2023 | Jul 21, 2023 (actual) |
| NCT04964323 | Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO) | Not listed | Terminated | Jul 2, 2021 | Jun 30, 2023 (actual) |
| NCT03548220 | A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) | Phase 3 | Completed | Aug 9, 2018 | Oct 9, 2020 (actual) |
| NCT03559699 | A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) | Phase 3 | Completed | Jun 26, 2018 | Nov 12, 2020 (actual) |
| NCT04128787 | A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881 | Phase 1 | Completed | Sep 30, 2019 | Dec 18, 2019 (actual) |
| NCT04696393 | A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants | Phase 1 | Completed | Jan 6, 2021 | Mar 19, 2021 (actual) |
| NCT04472832 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants | Phase 1 | Completed | Jun 17, 2020 | Nov 23, 2020 (actual) |
| NCT04565678 | A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants | Phase 1 | Completed | Sep 21, 2020 | Dec 3, 2020 (actual) |
| NCT03834584 | A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma | Phase 1 | Terminated | May 24, 2019 | Jun 17, 2020 (actual) |
| NCT04145128 | A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants | Phase 1 | Completed | Oct 2, 2019 | Dec 11, 2019 (actual) |
| NCT03361358 | Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma | Not listed | Completed | Mar 1, 2018 | Sep 30, 2019 (actual) |
| NCT03960502 | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881 | Phase 1 | Completed | May 16, 2019 | Sep 7, 2019 (actual) |
| NCT03991312 | Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants | Phase 1 | Completed | Jun 20, 2019 | Aug 14, 2019 (actual) |
| NCT04015687 | A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults | Phase 1 | Completed | Jul 15, 2019 | Oct 9, 2019 (actual) |
| NCT02492737 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | Phase 1 | Completed | Aug 7, 2015 | Mar 21, 2018 (actual) |
| NCT03703505 | A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348 | Phase 1 | Completed | May 24, 2018 | Jun 1, 2018 (actual) |
| NCT03245424 | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation | Not listed | Approved for marketing | Not listed | Not listed |
| NCT03282513 | A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function | Phase 1 | Completed | Sep 26, 2017 | Mar 31, 2018 (actual) |
| NCT03397329 | Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults | Phase 1 | Completed | Oct 3, 2017 | Nov 13, 2017 (actual) |
| NCT03071770 | Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects | Phase 1 | Completed | Mar 31, 2017 | May 9, 2017 (actual) |
| NCT03250598 | Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin | Phase 1 | Completed | Aug 9, 2017 | Oct 2, 2017 (actual) |
| NCT02630927 | A Safety and Tolerability Study of AG-519 in Healthy Subjects | Phase 1 | Terminated | 2015-12 | 2016-12 (actual) |
| NCT02831972 | Drug-Drug Interaction Study of AG120 in Healthy Subjects | Phase 1 | Completed | 2016-06 | 2016-09 (actual) |
| NCT02579707 | Food Effect Study of AG120 in Healthy Subjects | Phase 1 | Completed | 2015-10 | 2016-02 (actual) |
| NCT02489513 | Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 | Phase 1 | Completed | 2015-06 | 2015-09 (actual) |
| NCT02218346 | Food Effect Study of AG-221 in Healthy Male Subjects | Phase 1 | Completed | 2014-08 | 2014-12 (actual) |
FDA records (last 2 years)
- FDA New indication / efficacy supplement: AQVESME; PYRUKYND (mitapivat sulfate) — NDA216196/3, Dec 23, 2025. Applicant at approval: Agios Pharmaceuticals, Inc. source ↗
NIH awards 2
- NIH award 5R03DA032129-02 FY2012: $33,750 awarded for that fiscal year; activity R03 (OTHER_NIH); PI DANG, LENNY; recipient as written: AGIOS PHARMACEUTICALS, INC., CAMBRIDGE, MA. HTS for inhibitors of IDH1m & synthe source ↗
- NIH award 1R03DA032129-01 FY2011: $33,750 awarded for that fiscal year; activity R03 (OTHER_NIH); PI DANG, LENNY; recipient as written: AGIOS PHARMACEUTICALS, INC., CAMBRIDGE, MA. HTS for inhibitors of IDH1m & synthe source ↗
Raises and investors new
- InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗
Open jobs 15
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Hemolytic Anemia Sales Specialist / Senior Hemolytic Anemia Sales Specialist (National) | Agios Pharmaceuticals HQ | Not stated | Oct 15, 2026 | Mid |
| AD, Field Access Management (West) | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Mid |
| Director, Human Resources Business Partner | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Senior |
| Associate Director, Medical Review Lead, MSRM | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Senior |
| Associate Director, Value, Access, & Pricing (Ex-US) | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Senior |
| Director, US Commercial Risk Evaluation and Mitigation Strategies (REMS) Lead | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Senior |
| Hemolytic Anemia Sales Specialist (Michigan) | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Mid |
| Hemolytic Anemia Sales Specialist (Nashville) | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Mid |
| Hemolytic Anemia Sales Specialist (Pittsburgh) | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Mid |
| Medical Director/Senior Medical Director, Clinical Development | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Senior |
| Senior Director, Chemical Development & Manufacturing, CMC | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Senior |
| Senior Manager, Agios Clinical Educator (New York/Long Island) | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Senior |
| Senior Manager, Corporate Communications | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Senior |
| Sickle Cell Sales Specialist (Nashville) | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Mid |
| Sr. Manager/Associate Director, G&A Business Systems Analyst, IT | Agios Pharmaceuticals HQ | Not stated | Oct 12, 2026 | Senior |
Connect
See your connections at Agios Pharmaceuticals on LinkedIn (search by name, results not checked)